0.6495

5.94% -0.041

After Hours: .65 0.0005 +0.08%

Longeveron Inc (LGVN)

Overview News Price History Financials Why LGVN Down? Discussions Forecast

Longeveron Inc stock is traded at $0.6495, with a volume of 983.34K. It is down -5.94% in the last 24 hours and down -11.03% over the past month. Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Previous Close:

$0.6905

Open:

$0.62

24h Volume:

983.34K

Relative Volume:

2.01

Market Cap:

$20.52M

Revenue:

$1.22M

Net Income/Loss:

$-22.43M

P/E Ratio:

-0.5617

EPS:

-1.1564

Net Cash Flow:

$-18.78M

1W Performance:

-8.51%

1M Performance:

-11.03%

6M Performance:

+10.74%

1Y Performance:

-50.42%

1-Day Range:

$0.6003

$0.6899

1-Week Range:

$0.6003

$0.79

52-Week Range:

$0.475

$1.80

Longeveron Inc Stock (LGVN) Company Profile

Name

Longeveron Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

305-302-7158

Address

1951 NW 7TH AVENUE, MIAMI

Employee

Twitter

Next Earnings Date

2026-08-12

Latest SEC Filings

LGVN's Discussions on Twitter

Compare LGVN vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LGVN Longeveron Inc	0.6495	22.21M	1.22M	-22.43M	-18.78M	-1.1564
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Longeveron Inc Stock (LGVN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-06-24	Initiated	ROTH MKM	Buy

Longeveron Inc Stock (LGVN) Latest News

Jul 01, 2026

Price to sales forward of Longeveron Inc. – NASDAQ:LGVN - TradingView

Jul 01, 2026

Jun 30, 2026

Enterprise value to revenue forward of Longeveron Inc. – NASDAQ:LGVN - TradingView

Jun 30, 2026

Enterprise value to EBITDA forward of Longeveron Inc. – NASDAQ:LGVN - TradingView

Jun 30, 2026

Price to earnings forward of Longeveron Inc. – NASDAQ:LGVN - TradingView

Jun 30, 2026

Jun 29, 2026

LGVN Stock Slips After Hours As FDA Flags Concerns On Rare Heart Defect Trial Design - Stocktwits

Jun 29, 2026

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update - The National Law Review

Jun 29, 2026

Jun 27, 2026

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update - The National Law Review

Jun 27, 2026

LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty Study - Stocktwits

Jun 27, 2026

Jun 26, 2026